Indian Pharma Market - Covid-19 Induced Demand Pushes Growth To 47.8%: Anand Rathi

Favipiravir, the antiviral medication being manufactured in Russia. (Photographer: Andrey Rudakov/Bloomberg)

Indian Pharma Market - Covid-19 Induced Demand Pushes Growth To 47.8%: Anand Rathi


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Anand Rathi Report

On expected lines, the Indian pharma market grew at a robust 47.8% in May.

The Covid-19 outbreak had a marked impact on industry volumes last year and doctors are prescribing traditional anti-infective, gastrointestinal and respiratory brands to combat the second wave.

Acute therapy sales overall grew a strong 70.3%, while chronic and sub-chronic therapies grew 27.7% and 37.5% respectively.

Acute therapy growth was driven by a rebound in volumes and renewed demand for Covid-19 drugs.

On a lower base industry volumes grew 31.5%, a 7% blended price hike in May and launches contributed 9.3% of growth.

Click on the attachment to read the full report:

Anand Rathi Indian Pharma Sector Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.